Leading nutrition organizations issue call to prioritize child nutrition for a healthier, more prosperous Asia

As government, medical, academic and industry representatives gather at the first regional World Health Summit in Singapore, a group of nutrition organizations including global non-government organizations and Royal DSM called for urgent action to ensure adequate nutrition for children in their first 1,000 days of life.

A third of all children in Asia are stunted, or too short for their age - a key indicator of chronic malnutrition. Malnutrition during a child`s critical early years damages their intellectual and physical development, limiting their future economic participation, and increases their vulnerability to non-communicable diseases (NCDs) in adulthood. The World Bank estimates that India, where 48% of children are stunted and over 30% of children are born with a low birth weight, loses approximately 3% of annual GDP due to malnutrition.

The nutrition group, which includes World Vision, Save the Children, the Global Alliance for Improved Nutrition (GAIN), the Essential Micronutrients Foundation and industry partner Royal DSM, called on Summit delegates to commit to nutrition support as a key input to sustainable health and economic development outcomes. It called on governments to promote adequate health and nutrition for women of reproductive age, particularly pregnant and lactating women, to ensure their children have a head-start in good nutritional status. Through public-private partnerships, the private sector can support countries in improving diets by fortifying staples and making vitamin and mineral supplements affordable to the poor.

"The nutritional challenges faced by millions of children across Asia, coupled with increased economic inequality, can only be tackled through strong public-private partnerships. This combination of expertise and experience, with a profound sense of responsibility, are the very best tools we have for ridding the world of malnutrition," said Stephan Tanda, Managing Board Member of Royal DSM, on behalf of the group, adding that it welcomed interest and participation from key stakeholders across both sectors.

Singapore`s successes in maternal and child health can serve as a model for other countries. Since its independence, the country has achieved one of the lowest infant and under-five mortality rates in the world. With its strategic location and regional hub status in Asia, Singapore can play an important role in fostering greater public-private partnerships in the region to improve nutrition in the first 1,000 days.

Malnutrition is associated with poor feeding practices and other lack of access clean water, sanitation, healthcare, social protection and initiatives to empower women. There is compelling evidence connecting maternal nutrition to increased risks in their offspring of developing chronic disease, particularly diabetes and heart disease, later in life. Both undernutrition and overnutrition can have long term adverse effects. Of particular concern is the rapidly rising incidence of gestational diabetes and maternal obesity in Asia, which has major implications for the next generation.

"Economic growth alone will not solve the world`s nutrition problems - political leadership is absolutely necessary," asserted the group. "Governments must understand that investing in both mother and child nutrition, especially in the first 1000 days, means investing in their country`s economic future."

For more information:

DSM - Bright Science. Brighter Living.(TM) Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM`s 23,500 employees deliver annual net sales of about 9 billion. The company is listed on NYSE Euronext.

Global Alliance for Improved Nutrition (GAIN) Driven by a vision of a world without malnutrition, GAIN was created in 2002 at a Special Session of the U.N. General Assembly on Children. GAIN supports public-private partnerships to increase access to the missing nutrients in diets necessary for people, communities and economies to be stronger and healthier. With a current daily reach of over 667 million people in more than 30 countries, GAIN`s goal is to improve the lives of one billion people by 2015 within the most vulnerable populations around the world through access to sustainable nutrition solutions. Website: http://www.gainhealth.org/

View original post here:
Leading nutrition organizations issue call to prioritize child nutrition for a healthier, more prosperous Asia

Herbalife Becomes First Official Nutrition Sponsor of the 2013 Billboard Latin Music Conference and Awards

LOS ANGELES--(BUSINESS WIRE)--

Herbalife (HLF) announced an exclusive nutrition sponsorship deal with Latin musics premier event, the Billboard Latin Music Conference and Awards taking place in Miami on April 22-25.

As official nutrition sponsor of the Billboard Latin Music Conference and Awards, Herbalife will supply all attendees, speakers and artists with nutritious snacks such as protein bars, hydration and energy drinks throughout the event. Herbalife products will also be available at the VIP lounge for conference panelists at the JW Marriott Marquis, and at the Artist Gifting Suite at the BankUnited Center in Miami.

The 2013 Billboard Latin Music Conference and Awards Presented by State Farm in Association with Pepsi features three days of provocative presentations and panel discussions, exclusive Q&As, never-before-heard case studies from the biggest brands and digital marketers; cutting-edge artist showcases featuring some of the hottest acts; and access to parties and networking opportunities with senior executives and artists who are moving the industry forward. Registration to the Conference also includes access to the Billboard BASH a pre-Billboard Latin Music Awards party featuring performances by some of this years finalists - and The Billboard Latin Music Awards Presented by State Farm. The Billboard Latin Music Awards, produced and broadcast live by Telemundo, is the only recognition that truly reflects the best in Latin music, as determined by actual sales and radio play. For more information, please visit: http://www.BillboardLatinConference.com, or follow the event on: Facebook/Billboard and Twitter: @Billboard with the hashtag #BBLATIN.

We are truly excited about partnering this year with the Billboard Latin Music Conference and Awards and introducing our brand and our line of products to the Latin music community. We believe its a great fit and look forward to continue promoting a healthy lifestyle and keeping all conference attendees and talent properly hydrated and energized throughout the conference and during rehearsals, stated Ibi Fleming, senior vice president and managing director, Herbalife North America.

Herbalife, a global nutrition company that sells weight management, nutrition, and personal care products intended to support a healthy lifestyle, has traditionally been associated with sports sponsorships such as the Los Angeles Galaxy, FC Barcelona and Leo Messi. With this new agreement, Herbalife is expanding its brand awareness and exposure to the Latin music industry and hundreds of music professionals, including radio programmers and top recording Latin artists.

Having Herbalife join this years line of partners as official nutrition sponsor is a perfect match for our event, said Cebele Marquez, Sponsorship and Business Development Manager. We want to ensure that our conference attendees, speakers and participating artists stay healthy and properly energized during the multiple panel sessions and events leading up to the awards show on April 25. Were delighted to welcome Herbalife as a sponsor and look forward to a great program.

Herbalife also sponsors over 100 sporting events, teams and athletes around the world that reflect the companys commitment to a healthy active life supported by good nutrition. These sponsorships include the Herbalife Los Angeles Triathlon, and Pumas soccer club in Mexico.

About Herbalife Ltd.

Herbalife Ltd. (HLF) is a global nutrition company that sells weight management, nutrition and personal care products intended to support a healthy lifestyle. Herbalife products are sold in more than 80 countries to and through a network of independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife's website contains information about Herbalife, including financial and other information for investors at http://ir.Herbalife.com. The company encourages investors to visit its website from time to time, as information is updated and new information is posted.

Read more:
Herbalife Becomes First Official Nutrition Sponsor of the 2013 Billboard Latin Music Conference and Awards

Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale! – Video


Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale!
Présentation de la licence pro TCIBB, réalisée par la promo TCIBB 2012-2013. Pour tout renseignement : caroline.norez@univ-poitiers.fr.

By: Caroline Norez

Go here to read the rest:
Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale! - Video

CML HealthCare Inc. to Install North America’s First and World’s Largest Fully Automated BD Kiestraâ„¢ Microbiology …

MISSISSAUGA, Ontario, April 8, 2013 /PRNewswire/ --CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.

"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra TLA system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."

BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.

"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward-looking laboratory services providers," said Tom Polen, President, BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result.Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CMLwill be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier thus improving the standard of care and avoiding unnecessary healthcare costs."

The BD Kiestra TLA system currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.

About CML HealthCare Inc.

Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

For more information, please contact:

Read the original here:
CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestraâ„¢ Microbiology ...

CML HealthCare Inc. to Install North America’s First and World’s Largest Fully Automated BD Kiestra(TM) Microbiology …

MISSISSAUGA, ONTARIO--(Marketwired - Apr 8, 2013) - CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) ("BD"), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.

"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra Total Laboratory Automation system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."

BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.

"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward looking laboratory services provider," said Tom Polen, President BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result. Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CML will be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier - thus improving the standard of care and avoiding unnecessary healthcare costs."

The BD Kiestra TLA System currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.

About CML HealthCare Inc.

Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

Visit link:
CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestra(TM) Microbiology ...

New mouse viruses could aid hepatitis research

Public release date: 9-Apr-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Newly discovered mouse viruses could pave the way for future progress in hepatitis research, enabling scientists to study human disease and vaccines in the ultimate lab animal. In a study to be published in mBio, the online open-access journal of the American Society for Microbiology, scientists describe their search for viruses related to the human hepatitis C virus (HCV) and human pegiviruses (HPgV) in frozen stocks of wild mice. The discovery of several new species of hepaciviruses and pegiviruses that are closely related to human viruses suggests they might be used to study these diseases and potential vaccines in mice, without the need for human volunteers.

About 2% of the population is infected with the hepatitis C virus and 5% is infected with human pegiviruses, but it's been difficult to study new drugs or develop vaccines against these infections because the human strains do not infect animals that can be studied in the lab. Lead author Amit Kapoor of Columbia University says it surprised him to find similar viruses in mice.

"People have been waiting for decades to find something like this. It was shocking for me to see that the viruses are there and there are so many of them," says Kapoor.

Kapoor and his colleagues screened an archive of more than 400 frozen rodents, mostly deer mice, for viruses related to the human hepatitis C virus and human pegiviruses. The search turned up a number of candidates, and they selected two for complete genome sequencing: a rodent hepacivirus (RHV) found in deer mice and a rodent pegivirus (RPgV) found in a white-throated woodrat. Sequencing confirmed that the viruses are very closely related to human strains but they represent several novel species in the Hepacivirus and Pegivirus genera within the family Flaviviridae.

These rodent viruses have genes, proteins, and translational elements that closely mirror those found in human hepaciviruses and pegiviruses, suggesting they have great potential for use in the lab. Animal models of hepatitis would help scientists explore the ways these viruses causes disease and aid in the design of treatments and vaccines. Human pegiviruses, on the other hand, have unknown effects, so studying how they work in rodents could well point the way to what they might do in the human body and why so many people are infected.

Kapoor's lab is now focused on exploring the biology of these viruses. "We are trying to infect deer mice, to study biological properties of these hepatitis C-like viruses," says Kapoor. "And if we find one of these viruses is hepatotrophic [having an attraction to the liver] and causes disease similar to hepatitis C, that would be a big step forward in understanding hepatitis C-induced pathology in humans."

###

mBio is an open access online journal published by the American Society for Microbiology to make microbiology research broadly accessible. The focus of the journal is on rapid publication of cutting-edge research spanning the entire spectrum of microbiology and related fields. It can be found online at http://mbio.asm.org.

More here:
New mouse viruses could aid hepatitis research

Reagent aids scientists in mitochondrial dysfunction analysis.

XF PMP was developed in partnership with the Pioneer Valley Life Sciences Institute (PVLSI), a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. The technology was exclusively licensed to Seahorse Bioscience by UMass Amherst and Baystate Health, the parent organization of Baystate Medical Center.

XF PMP can be used with the Seahorse XF(e) Extracellular Flux Analyzer, an instrument for measuring cell metabolism, in real-time, in a microplate. The reagent was developed for XF technology in part by Dr. Nagendra Yadava, the John Adams Investigator at PVLSI; and Dr. Alejandro Heuck, Ph.D., an Assistant Professor of Biochemistry and Molecular Biology at UMass Amherst.

"In the development of this potent new tool in biomedical analysis, we see the tremendous potential of collaborations between clinical and academic researchers and ingenuitive companies like Seahorse," said Richard Friedberg, M.D., Ph.D., chair of Pathology and chair of the Intellectual Property Committee at Baystate Health, who represented Baystate in working with Seahorse and UMass to establish the licensing agreement.

XF PMP creates pores in the cell plasma membrane, and delivers a degree of precision and ease-of-use that has not been available to scientists researching cell metabolism. A key element of XF PMP is the ability to assess mitochondrial function in adherent monolayers of permeabilized cells without damaging the mitochondrial membrane. By doing so, XF PMP enables metabolic substrates, compounds, and small proteins that otherwise would not cross the plasma membrane to reach the mitochondria.

"Seahorse's new XF Plasma Membrane Permeabilizer [PMP] enabled us to demonstrate that clinically-relevant concentrations of thiazolidinediones, a class of insulin sensitizers that includes Actos, specifically inhibited the mitochondrial pyruvate carrier, a protein at the hub of cellular metabolism. The simplicity and reliability of XF PMP made it easy to interrogate the mitochondrial function of small clinical samples and genetically modified cells without mitochondrial isolation, experiments that are traditionally difficult or impossible. Our work is providing a new understanding of the mechanism of action of an important class of drugs, and opens a new avenue for the development of drugs to treat diseases including type 2 diabetes, neurodegenerative disease, and heart failure," stated Anne N. Murphy, Ph.D., Associate Professor of Pharmacology at University of California, San Diego.

About Seahorse Bioscience Seahorse Bioscience provides industry-leading analytical instruments, cell-based assay kits, and consumable labware products for biological research and drug discovery. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial dysfunction in cancer, neuroscience, immunology, obesity, diabetes, ageing, cardiovascular function, and safety toxicity. Seahorse is headquartered in Billerica, Massachusetts; has its manufacturing facilities in Chicopee, Massachusetts; and regional headquarters in Copenhagen and Shanghai. For more information visit: http://www.seahorsebio.com.

About Baystate Medical Center Baystate Medical Center is an academic, research and teaching hospital that serves as the western campus of Tufts University School of Medicine. It is the major referral care center and only Level 1 trauma center for western Massachusetts, and is home to one of New England's busiest emergency rooms. One of Thomson Reuters/Truven Health Analytics' top 50 U.S. hospitals for cardiovascular care and top 100 U.S. hospitals, Baystate Medical Center is also designated a Leapfrog Top Hospital for quality and safety, is a Magnet hospital for nursing excellence, and is a six-time winner of the Beacon Award for Critical Care Excellence. http://www.baystatehealth.org/bmc

About the University of Massachusetts Amherst The University of Massachusetts Amherst, the flagship campus of the UMass system, is one of the nation's top public research universities with 28,000 students studying in the scenic Pioneer Valley of Western Massachusetts. Celebrating its 150th anniversary in 2013, UMass Amherst offers 108 undergraduate degree programs (including six associate degrees) as well as 76 masters and 50 doctoral programs. For more information visit: http://www.umass.edu.

About the Pioneer Valley Life Sciences Institute PVLSI was created in 2002 as a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. Drawing on each of the founders as well as its own researchers, the Institute brings together physicians, scientists, and engineers to create interdisciplinary and multidisciplinary teams focused on the molecular mechanisms of disease and the development of new diagnostic and therapeutic tools. For more information visit: http://www.pvlsi.org.

Contact: Naomi Goumillout, 1-978-671-1619, ngoumillout@seahorsebio.com

Link:
Reagent aids scientists in mitochondrial dysfunction analysis.

Age Rejuvenation Centers – The Future of Healthcare | Look and Feel 20 years younger – Video


Age Rejuvenation Centers - The Future of Healthcare | Look and Feel 20 years younger
http://www.Agerejuvenationcenters.com Age Rejuvenation Center "Do you feel sluggish or tired? Are you overweight? Are you living life to the fullest? Hormone Replac...

By: AgeRejuvenationCtrs

Go here to see the original:
Age Rejuvenation Centers - The Future of Healthcare | Look and Feel 20 years younger - Video

Data Presented on Bayer's ATX-101 – Analyst Blog

Bayer AG ( BAYRY ) recently presented positive results on ATX-101 at the 11th Anti-Aging Medicine World Congress (AMWC) 2013. ATX-101 is being developed for the reduction of unwanted fat deposits under the chin- submental fat (SMF).

Results from a phase IIa study showed that ATX-101 significantly and consistently reduces SMF. The level of SMF reduction was sustained in more than 90% patients who responded to treatment. Moreover, treatment satisfaction was sustained in more than 80% of these patients.

Results from another phase I pharmaco-kinetic study showed that the permanent destruction of fat cells (adipocytolysis) made by ATX-101 did not have any clinically significant impact on the serum lipid levels of the patients in the study. Notably, ATX-101 is the first injectable candidate being evaluated as a non-surgical treatment for SMF reduction in a comprehensive clinical trial setting.

In Feb 2013, Bayer presented positive results from two European phase III studies on ATX-101 at the International Master Course on Aging Skin (IMCAS). Results from the studies showed that ATX-101 reduced SMF more than placebo. ATX-101 demonstrated significant improvement in clinician-reported measurements of SMF, supported by objective caliper measurements of SMF thickness, in comparison to placebo.

Results also revealed that patients were more satisfied with their chin appearance and their treatment with ATX-101 than placebo. The candidate was well tolerated in both the studies.

We note that the studies are part of the ATX-101 clinical development program which is being conducted jointly by Bayer and Kythera Biopharmaceuticals Inc. ( KYTH ) since 2010. As per the 2010 licensing deal between the companies, Bayer acquired rights to ATX-101 in markets outside the US and Canada.

Kythera is eligible to receive tiered double-digit royalties on the sales of the drug made by Bayer outside the US and Canada. Kythera and Bayer have however collaborated to develop ATX-101 in Europe.

In Nov 2012, Kythera had reported positive interim results from a multicenter, open-label, long-term study on ATX-101. The study revealed that the candidate was well tolerated and demonstrated a similar safety profile to that observed in previous studies conducted with the candidate.

We note that Bayer suffered a huge setback last month when the company and its partner Johnson & Johnson ( JNJ ) received a second complete response letter (CRL) from the US Food and Drug Administration (FDA) for their supplemental New Drug Application (sNDA) for Xarelto (2.5 mg twice daily) for the reduction of the risk of secondary cardiovascular events in patients suffering from ACS.

The second CRL for Xarelto is a big disappointment for the company. Bayer carries a Zacks Rank #4 (Sell). The setback regarding Xarelto is primarily responsible for the bearish rank carried by the company. Cytokinetics Inc. ( CYTK ) currently looks better positioned in the pharma space carrying a Zacks Rank #1 (Strong Buy).

See the article here:
Data Presented on Bayer's ATX-101 - Analyst Blog

GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy

PARIS, April 8, 2013 /PRNewswire/ --

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a 32 million Series A financing.

The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP). The lead product is expected to enter the clinic in 2013 in LHON patients.

Bernard Gilly, co-founder and CEO of GenSight is a successful bio-entrepreneur, was formerly CEO of Fovea Pharmaceuticals (which was acquired by sanofi-aventis in 2009), a partner at Sofinnova Partners and CEO of Transgene, a publicly traded gene therapy company. GenSight co-founder, Professor Jos-Alain Sahel, is Chairman of the Vision Institute in Paris. Botond Roska, a specialist in the structure and function of neural circuits at the FMI (Basel), has been pioneering the field of optogenetics. Jean Bennett, Professor of Ophthalmology, University of Pennsylvania, and also a co-founder of GenSight, has successfully conducted gene therapy trials to treat a rare retinal degeneration. The other co-founders of GenSight are Connie Cepko Professor of Genetics at Harvard (Boston), Ernst Bamberg Professor at The Max Planck Institute (Frankfurt), Luk Vandenberghe at the Schepens Eye Research Institute(Boston) and Serge Picaud at the Vision Institute (Paris).

Bernard Gilly commented: "Gene therapy is coming of age and ophthalmology is one of the most promising indications in particular because of the safety and efficacy demonstrated in certain trials. GenSight has a unique, proprietary approach to targeting the mitochondria in LHON developed by Dr Corral-Debrinsky and Jose Sahel at the Vision Institute, and exclusive access to key intellectual property from Novartis for using optogenetics to treat RP patients. Our outstanding links to leading ophthalmology physicians and scientists on both sides of the Atlantic, our strong link with the Foundation Fighting Blindness, our partnership with AFM/Genethon and our experienced management team are key to successfully moving our products through clinical developments to proof of efficacy."

"We are delighted to be working with GenSight and the other investors to assist the company in progressing its highly innovative technology and gene-based therapeutics towards the clinic. Gene therapy represents a new frontier in targeting ophthalmic diseases, and GenSight's expertise and capabilities are outstanding," said Florent Gros of Novartis Venture Fund, who will join the board of directors, along with Dr Genghis Lloyd-Harris (Abingworth) and Dr Guido Magni (Versant).

GenSight is based in Paris, France on the campus of the Vision Institute. Please visit our website http://www.gensight-biologics.com

Notes for Editors

About Novartis Venture Fund

The Novartis Venture Funds manages over $850 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that will be critical to patient care. Our primary interest is in the development of novel therapeutics and platforms as well as medical devices, diagnostics, and delivery systems. The Funds invest for financial objectives at all stages, but prefers to invest in the early-stages of company development. With ten investment professionals located in Basel, Switzerland and Cambridge, MA the team has extensive experience in pharmaceutical R&D and venture capital.

Read the rest here:

GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy